Document is current
Any future updates will be listed below
-
Authors
Kerem, Liya
Hadjikhani, Nouchine http://orcid.org/0000-0003-4075-3106
Holsen, Laura
Lawson, Elizabeth A.
Plessow, Franziska http://orcid.org/0000-0002-9721-7817
- License Information
-
More Information
Article History
Received: 4 May 2019
Revised: 11 October 2019
Accepted: 31 October 2019
First Online: 18 November 2019
Compliance with ethical standards
:
: The study was supported by the Boston Nutrition Obesity Research Center—5P30DK046200-20; Nutrition Obesity Research Center at Harvard—P30DK040561; 5R01DK109932-02; K23 MH092560; K24 MH120568; and Harvard Clinical and Translational Science Center 0UL1TR001102-01. EAL has a financial interest in OXT Therapeutics, a company developing an IN OXT and long-acting analogs of OXT to treat obesity and metabolic disease. EAL’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. This company was not involved in any way in this research. The other authors declare that they have no conflict of interest.
